Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bristol-Myers Squibb Company SEC filings document the company’s pharmaceutical operating results, investor presentations, governance matters, registered securities and debt activity. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD presentations, annual-meeting vote results and other material events, including note offerings and tender-offer disclosures tied to the company’s capital structure.
The company’s proxy materials cover board elections, executive compensation, shareholder voting matters and corporate governance. Its registered securities disclosures include common stock, Celgene contingent value rights and multiple exchange-listed notes. Form 15 records also document the termination of registration for a $2 convertible preferred stock class with no holders of record, while other reporting obligations remain tied to listed securities.
Bristol-Myers Squibb (BMY) filed an 8-K on 31-Jul-2025 to furnish, rather than file, its second-quarter 2025 earnings materials.
- Item 2.02: Exhibit 99.1 is the press release containing Q2-25 results.
- Item 7.01: Exhibit 99.2 is an investor presentation used for the 8:00 a.m. ET conference call.
- Both exhibits include non-GAAP figures with GAAP reconciliations; no financial metrics appear in the body of the 8-K itself.
- The furnished status limits Exchange Act §18 liability and prevents automatic incorporation into future filings unless specifically referenced.
- No other material transactions, governance changes or financing actions were disclosed.
The filing also lists NYSE-traded securities—common stock, 1.750 % notes due 2035, and Celgene CVRs—and contains standard emerging-growth-company and Regulation FD boilerplate.
Form 8-K – Item 5.02 (Departure of Certain Officers)
On 25 July 2025, Bristol-Myers Squibb Company (NYSE: BMY) reported that Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer & Head of Development, will step down from these roles effective 1 August 2025 and will fully exit the company on or before 1 November 2025. During the interim period he will act as an advisor.
Separation terms
- Cash severance governed by the U.S. Severance Benefits Plan.
- Pro-rated vesting of outstanding Market Share Units and Performance Share Units under the 2021 Stock Award & Incentive Plan.
- Prorated 2025 annual incentive under the Senior Executive Performance Incentive Plan.
No successor, strategic changes, or financial impact projections were disclosed. A related press release is furnished as Exhibit 99.1.